Mirabet Tablets 50Mg (1 Strip = 10 Tablets)

Requires Prescription (YES/NO)

Yes

Generics

Mirabegron

Used For

Urinary Incontinence

How it works

Mirabegron is an agonist of the human beta-3 adrenergic receptor (AR). Mirabegron relaxes the detrusor smooth muscle during the storage phase of the urinary bladder fill-void cycle by activation of beta-3 ARwhich increases bladder capacity.

Dosage

Mirabegron

Side Effects

Common : Urinary tract infection, tachycardia, nausea, constipation, diarrhea, headache and dizziness.Uncommon : Vaginal infection, cystitis, palpitation, atrial fibrillation, dyspepsia, gastritis, urticaria, rash, rash macular, rash popular, pruritis, joint swelling, vulvovaginal pruritus, blood pressure increased, GGTincreased, AST increased and ALT increased.Rare : Eyelid edema, lip edema, leukocytoclastic vasculitis, purpura, angioedema and urinary retention.

Drug Interactions

Digoxin , Warfarin , CYP2D6 enzyme such as metoprolol and desipramine , CYP2D6, such as thioridazine, Type 1C antiarrhythmics (e.g., flecainide, propafenone) and tricyclic antidepressants (e.g., imipramine, desipramine)

Indication

Mirabegron is indicated for the symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.

When not to Use

Mirabegron is contraindicated;- In patients with known hypersensitivity to mirabegron or to any excipient of the product.- Severe uncontrolled hypertension defined as systolic blood pressure =180 mm Hg and/or diastolic blood pressure =110 mm Hg.

Precaution

Mirabegron can increase blood pressure. Periodic blood pressure determinations are recommended, especially in hypertensive patients.

Warning 1

Urinary retention in patients with bladder outlet obstruction (BOO) and in patients taking antimuscarinic medications for the treatment of OAB has been reported in patients taking mirabegron. Mirabegron should be administered with caution to patients with clinically significant BOO. Mirabegron should also be administered with caution to patients taking antimuscarinic medications for the treatment of OAB.

Warning 2

Angioedema of the face, lips, tongue and/or larynx has been reported with mirabegron. In some cases angioedema occurred after the first dose. Cases of angioedema have been reported to occur hours afterthe first dose or after multiple doses. Angioedema associated with upper airway swelling may be life threatening. If involvement of the tongue, hypopharynx or larynx occurs, promptly discontinue mirabegron and initiate appropriate therapy and/or measures necessary to ensure a patent airway .

Warning 3

Caution should be exercised when administering mirabegron in patients with a known history of QT prolongation or patients who are taking medicinal products known to prolong the QT interval.

Pregnancy category

Always consult your physician before using any medicine.

Storage (YES/NO)

Store this medicine at room temperature, away from direct light and heat.